Fulcrum Therapeutics, Inc. (FULC)
FULC moved a median of -0.41% 30 minutes after news, and -0.28% by the close. How FULC actually reacts to news — the realized, point-in-time move the market made, measured across 369 labeled events over the last three years with zero look-ahead.
FULC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 369 |
| 30-min | -0.41% | 44% | 369 |
| 60-min | -0.62% | 39% | 369 |
| to close | -0.28% | 48% | 361 |
| Middle 50% of FULC reactions | -1.57% to +1.30% |
|---|---|
| Median reaction (30-min) | -0.41% |
| Measured reactions | 369 |
Half of all Fulcrum Therapeutics, Inc. news events land between -1.57% and +1.30% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How FULC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | -0.73% | 35% | -1.33% |
| Analyst downgrades | 36 | -1.45% | 39% | +0.96% |
| Coverage initiations | 16 | -0.24% | 25% | -0.13% |
| Rating reiterations | 42 | +0.30% | 52% | -0.28% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how FULC ranks against every other measured name →
That’s how FULC usually reacts — get an email when it moves on news →Email me when FULC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to FULC's baseline. Nothing else.
Recent FULC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form S-4/A Fulcrum Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | +0.27% | +0.53% | |
| Are FULC, TCBK, LXP Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | -0.13% | |
| Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | +0.00% | +0.13% | |
| FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | -0.26% | +0.00% | |
| Are UTZ, ITGR, FULC Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.13% | -0.13% | |
| Form S-4 Fulcrum Therapeutics, | SEC filing · Form S-4 | SEC EDGAR | +0.26% | -0.77% | |
| Are WEAV, FULC, BRBS Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.26% | +0.00% | |
| BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TE | Press release | GlobeNewswire | +0.00% | +0.66% | |
| Are MITT, ARX, HHS, FULC Obtaining Fair Deals for their Shareholders? | Press release | PR Newswire | -0.26% | +0.52% | |
| Form 8-K Fulcrum Therapeutics, For: Aug 16 | SEC filing · Form 8-K | SEC EDGAR | +1.57% | +0.79% | |
| FULC Stock Alert: Halper Sadeh LLC is Investigating Whether Fulcrum Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders | Press release | Business Wire | +1.57% | +0.79% | |
| Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies | Press release | GlobeNewswire | +1.57% | +0.79% | |
| Form 8-K Fulcrum Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | — | |
| Form 10-Q Fulcrum Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.34% | -3.76% | |
| Form 8-K Fulcrum Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | +5.26% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulcrum Therapeutics, Inc. (FULC) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +1.35% | +2.17% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.29% | +6.63% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.97% | -3.75% | |
| Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.14% | -2.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.14% | -3.09% | |
| Form 8-K Fulcrum Therapeutics, For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | -0.28% | -3.09% | |
| Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.29% | +3.54% | |
| Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.15% | +3.08% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.00% | -1.29% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Fulcrum Therapeutics, Inc. (FULC) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +1.70% | -2.55% | |
| Form 8-K Fulcrum Therapeutics, For: May 31 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | +10.15% | |
| FULC SHAREHOLDER INVESTIGATION: SueWallSt Investigates Fulcrum Therapeutics, Inc. for Possible Securities Law Violations | Press release | PR Newswire | -0.32% | +3.54% | |
| Form 8-K Fulcrum Therapeutics, For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +0.96% | |
| Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | Press release | GlobeNewswire | +0.16% | +0.96% | |
| Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.63% | -2.91% | |
| Form ARS Fulcrum Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.70% | +3.52% | |
| Form DEF 14A Fulcrum Therapeutics, For: Jun 24 | SEC filing · Form DEF | SEC EDGAR | +0.70% | +3.52% | |
| Form DEFA14A Fulcrum Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | +0.70% | +3.52% | |
| Form 10-Q Fulcrum Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -9.75% | -2.28% | |
| Form 8-K Fulcrum Therapeutics, For: Apr 23 | SEC filing · Form 8-K | SEC EDGAR | -9.75% | -2.28% | |
| Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026 | Press release | GlobeNewswire | -9.75% | -2.28% | |
| Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors | Press release | GlobeNewswire | -9.75% | -2.28% | |
| Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8:00 a.m. ET | Press release | GlobeNewswire | -0.85% | -3.52% | |
| MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease | Press release | GlobeNewswire | -1.89% | +2.48% | |
| Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.92% | +1.53% | |
| Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference | Press release | GlobeNewswire | +0.33% | +2.61% | |
| Form 10-K Fulcrum Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.59% | -11.09% | |
| Form 8-K Fulcrum Therapeutics, For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | -2.59% | -11.09% | |
| Form S-8 Fulcrum Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -2.59% | -11.09% | |
| Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease | Press release | GlobeNewswire | -2.59% | -11.09% | |
| Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 | Press release | GlobeNewswire | -2.59% | -11.09% | |
| Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease | Press release | GlobeNewswire | +0.48% | +1.43% | |
| Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.72% | +4.60% | |
| Form 8-K Fulcrum Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.73% | -8.47% | |
| Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -1.73% | -8.47% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the FULC section they belong to.
Where else FULC is measured.
FULC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Fulcrum Therapeutics, Inc.'s median reaction calculated?
Every labeled FULC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 369 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 44% of FULC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does FULC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.